Drug Design and Development for Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. Despite decades of research, effective curative treatments remain elusive. This article explores current strategies in drug design and development for Alzheimer’s disease, highlighting recent advancements, challenges, and future perspectives. Emphasis is placed on amyloid-beta and tau-targeting agents, cholinesterase inhibitors, NMDA receptor antagonists, and novel therapeutics emerging from precision medicine and artificial intelligence. The importance of early diagnosis, biomarkers, and blood-brain barrier permeability in drug development is also discussed. An integrated and multidisciplinary approach is essential for therapeutic breakthroughs in AD.